A survey conducted in seven Asian markets, including Indonesia, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondents expressed a low to moderate level of knowledge about infertility and conception. Unexpected emotional burden and fear emerged as primary factors causing delays in seeking medical treatment. The journey was marked by a rollercoaster of emotional highs and lows.1,2

JAKARTA, Indonesia, Nov. 7, 2023 /PRNewswire/ — Today, Ferring Pharmaceuticals released a white paper report titled "Real Voices, New Insights: Eureka Moments for Fertility in Asia" integrating findings from a multi-country survey ("EUREKA") across seven countries in Asia involving over 1,465 respondents who were considering, receiving, or have completed fertility treatments.1,2 Supported by publications and experts’ opinion, the insights reported can help guide couples, the public and governments to better understand the infertility journey in light of the declining births crisis emerging in many Asian countries, including here in Indonesia.

"Many Asian countries are facing an unprecedented decline in birth rates. As a leader in reproductive medicine, Ferring is committed to building families worldwide and supporting the journey to parenthood. The EUREKA survey is one of the first in our region involving seven countries highlighting the increasing importance to understand the emotional journey of many couples to increase education and community awareness" said Alex Chang, Senior Vice President of Asia Pacific, Middle East, and Africa, Ferring Pharmaceuticals.

The journey of conception is long for many couples in Asia
The white paper reported that the fertility journey of survey respondents – from deciding to have a baby, diagnosis, treatment to eventual conception – took an average of 6.8 years, out of which, an average of 3.6 years trying to conceive naturally,1,2 which is more than three times the duration recommended by the World Health Organization in defining infertility warranting medical consultation.3

Notably, those living in countries and regions such as Japan, Korea, Taiwan and Singapore – where fertility treatments are covered by national health schemes either through reimbursements or subsidies, reported an average of 1.6 years after diagnosis to start treatment.1,2 Age and duration impact conception success.4 It is thus important to raise awareness on seeking professional advice sooner as waiting may lead to a lower chance of successful conception owing to older age.

Associate Professor Sadhana Nadarajah, Head and Senior Consultant, Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, said that "[a] woman’s age is an important determinant of fertility. With increasing age, both egg quality and quantity decline, especially after 35. By the age of 40, only 20–30 percent of those who wish to have a baby will be able to do so."

Echoing the role that age plays in one’s fertility journey, Dr Chen Mei-Jou, President of Taiwanese Society for Reproductive Medicine, mentioned that "there is an obvious and significant difference in terms of the success rate of IVF treatment at the ages of 35, 38 and above 40. In Taiwan, the biggest problem encountered by fertility physicians is that patients often seek help very late into their fertility journey, and some may have even waited for years after trying to conceive naturally."

Knowledge gaps inevitably delay the fertility journey
It was identified that there was a general lack of understanding and lots of misconceptions of infertility. Many were unfamiliar with key fertility concepts, inadvertently delaying taking the first step towards family planning.  

At least seven out of 10 respondents from Indonesia, Japan, Korea, Singapore and Vietnam self-reported low-to-moderate knowledge of infertility and conception before they were diagnosed with fertility issues. They had limited knowledge about key fertility concepts and wished they had known earlier:1

How infertility affects both genders How age impacts the quantity and quality of eggs, or ovarian reserve, which influences the overall chances of natural conception How the success of fertility treatments can be age-dependent despite medical advances

Associate Professor Sadhana Nadarajah, Head and Senior Consultant, Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, mentioned that "couples need to know when and how to seek fertility assessment. More can be done to create greater awareness such as via social media platforms and public forums."

Respondents from the survey also indicated that they depended heavily on online platforms and channels as a key source of fertility-related information which was identified in the report to be at high risk of misinformation and bias.1,2  

Emotional support is critical
The report also highlighted findings on the emotional rollercoaster the respondents underwent. Regardless of treatment outcomes, the diagnosis and treatment of infertility was a highly emotional experience. Psychological factors are among the most frequently cited reasons for patients dropping out of fertility treatments, often in the earliest stages of treatment.5 In Asia, the EUREKA survey found that couples often struggled with high levels of emotional strain:1,2 

Unexpected emotional burden was a major pain point and fear was often cited as a primary reason against starting treatment. In Indonesia, 35 percent of respondents cited unexpected emotional burden and 28 percent cited fear of treatment response as top barriers for starting treatment. Other top barriers included concerns on treatment effects, treatment cost and workplace challenges. At all timepoints, there was a fluctuation between positive and negative emotions. Even for respondents who achieved successful conception, considerable negative emotions continued to persist. The prolonged mix of emotions can be of significant burden to the couple and their motivation to continue.

For example, in Singapore, men and women were equally anxious at diagnosis. Katy, a 38-year-old from Singapore, shared that "the period of trying to achieve pregnancy is something that is hard to forget. All the injections, reviews, waiting, hope, and anticipation. In many cases, couples would have to try again and again to succeed, and it gets even harder with each failure."

In Indonesia, infertility treatments remained predominantly self-pay. While countries and regions such as Singapore, Japan, Korea, and Taiwan have started recognizing the growing need to increase access to infertility treatments through various national financial coverage schemes, like Indonesia, emotional support remains a missing piece. At present, mental health remains underprioritized in the treatment of infertility and the provision of emotional support from various sources is critical.

About the White Paper – Real Voices, New Insights: Eureka Moments for Fertility in Asia
Everyone has a right to build a family, even in the face of biological and social barriers. The decision to have children is a personal one and we support families of all shapes and sizes. Having the right information empowers people to make the right decision at the right time, and demystifying infertility allows thoughtfulness and empathy to grow within communities and workplaces to better support their friends, families, and employees. The "Real Voices, New Insights: Eureka Moments for Fertility in Asia" white paper was commissioned by Ferring in collaboration with Weber Shandwick to provide insights into the journey towards parenthood based on EUREKA – a large scale survey conducted across the Asia Pacific region, supported by various peer-reviewed publications and experts’ opinion. It provides a concise, reliable, and informative resource that could be used to guide more couples in realizing their dreams of building a family. The full white paper is now available at https://re.ferring.com/eureka. 

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References
1 "Ipsos Pte Ltd, Singapore (2022). Study on key Asian insights in family building dreams (EUREKA), unpublished"
2 "Ipsos Limited, Taiwan (2022). Infertility patient and partner survey: 1000 Dreams in Taiwan (EUREKA), unpublished"
3 World Health Organization. Infertility. Available at: https://www.who.int/news-room/fact-sheets/detail/infertility
4 ASRM. Age and Fertility – A Guide for Patients: Available at: https://www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/factsheets-and-info-booklets/age-and-fertility/. Accessed Mar 2023.
5 Sax MR & Lawson AK. Women 2022; 2:68–75.

Source : Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

A survey conducted in seven Asian markets, including Singapore, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondents expressed a low to moderate level of knowledge about infertility and conception. In Singapore, this figure soared to 76 percent.1 Unexpected emotional burden and fear emerged as primary factors causing delays in seeking medical treatment. The journey was marked by a rollercoaster of emotional highs and lows.1,2

SINGAPORE, Nov. 7, 2023 /PRNewswire/ — Today, Ferring Pharmaceuticals released a white paper report titled "Real Voices, New Insights: Eureka Moments for Fertility in Asia" integrating findings from a multi-country survey ("EUREKA") across seven countries in Asia involving over 1,465 respondents who were considering, receiving, or have completed fertility treatments.1,2 Supported by publications and experts’ opinion, the insights reported can help guide couples, the public and governments to better understand the infertility journey in light of the declining births crisis emerging in many Asian countries, including here in Singapore.

"Many Asian countries are facing an unprecedented decline in birth rates. As a leader in reproductive medicine, Ferring is committed to building families worldwide and supporting the journey to parenthood. The EUREKA survey is one of the first in our region involving seven countries highlighting the increasing importance to understand the emotional journey of many couples to increase education and community awareness" said Alex Chang, Senior Vice President of Asia Pacific, Middle East, and Africa, Ferring Pharmaceuticals.

The journey of conception is long for many couples in Asia
The white paper reported that the fertility journey of survey respondents – from deciding to have a baby, diagnosis, treatment to eventual conception – took an average of 6.8 years, out of which, an average of 3.6 years trying to conceive naturally,1,2 which is more than three times the duration recommended by the World Health Organization in defining infertility warranting medical consultation.3

Notably, those living in countries and regions such as Japan, Korea, Taiwan and Singapore – where fertility treatments are covered by national health schemes either through reimbursements or subsidies, reported an average of 1.6 years after diagnosis to start treatment.1,2 Age and duration impact conception success.4 It is thus important to raise awareness on seeking professional advice sooner as waiting may lead to a lower chance of successful conception owing to older age.

Associate Professor Sadhana Nadarajah, Head and Senior Consultant, Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, said that "[a] woman’s age is an important determinant of fertility. With increasing age, both egg quality and quantity decline, especially after 35. By the age of 40, only 20–30 percent of those who wish to have a baby will be able to do so."

Echoing the role that age plays in one’s fertility journey, Dr Chen Mei-Jou, President of Taiwanese Society for Reproductive Medicine, mentioned that "there is an obvious and significant difference in terms of the success rate of IVF treatment at the ages of 35, 38 and above 40. In Taiwan, the biggest problem encountered by fertility physicians is that patients often seek help very late into their fertility journey, and some may have even waited for years after trying to conceive naturally."

Knowledge gaps inevitably delay the fertility journey
It was identified that there was a general lack of understanding and lots of misconceptions of infertility. Many were unfamiliar with key fertility concepts, inadvertently delaying taking the first step towards family planning.  

At least seven out of 10 respondents from Indonesia, Japan, Korea, Singapore and Vietnam self-reported low-to-moderate knowledge of infertility and conception before they were diagnosed with fertility issues, increasing to almost 76 percent of respondents in Singapore. They had limited knowledge about key fertility concepts and wished they had known earlier:1

How infertility affects both genders How age impacts the quantity and quality of eggs, or ovarian reserve, which influences the overall chances of natural conception How the success of fertility treatments can be age-dependent despite medical advances

In Singapore, 40 percent of respondents were unaware of AMH as a fertility marker. Associate Professor Sadhana Nadarajah, Head and Senior Consultant, Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, mentioned that "couples need to know when and how to seek fertility assessment. More can be done to create greater awareness such as via social media platforms and public forums."

Respondents from the survey also indicated that they depended heavily on online platforms and channels as a key source of fertility-related information which was identified in the report to be at high risk of misinformation and bias.1,2  

Emotional support is critical
The report also highlighted findings on the emotional rollercoaster the respondents underwent. Regardless of treatment outcomes, the diagnosis and treatment of infertility was a highly emotional experience. Psychological factors are among the most frequently cited reasons for patients dropping out of fertility treatments, often in the earliest stages of treatment.5 In Asia, the EUREKA survey found that couples often struggled with high levels of emotional strain:1,2 

Unexpected emotional burden was a major pain point for respondents in their treatment journey and fear was often cited as a primary reason against starting treatment for those who did not proceed. In Singapore, close to 1 in 3 cited unexpected emotional burden and 1 in 4 cited fear as top barriers during their treatment journey. Other pain points included concerns on unexpected costs, concerns on multiples in conception (twins and more) and also not understanding their condition fully.  At all timepoints, there was a fluctuation between positive and negative emotions. Even for respondents who achieved successful conception, considerable negative emotions continued to persist. The prolonged mix of emotions can be of significant burden to the couple and their motivation to continue.

For example, in Singapore, men and women were equally anxious at diagnosis. Katy, a 38-year-old from Singapore, shared that "the period of trying to achieve pregnancy is something that is hard to forget. All the injections, reviews, waiting, hope and anticipation. In many cases, couples would have to try again and again to succeed, and it gets even harder with each failure."

While countries and regions including Singapore, Japan, Korea, and Taiwan have started recognizing the growing need to increase access to infertility treatments through various national financial coverage schemes, emotional support remains a missing piece for many. At present, mental health remains underprioritized in the treatment of infertility and the provision of emotional support from various sources is critical.

About the White Paper – Real Voices, New Insights: Eureka Moments for Fertility in Asia
Everyone has a right to build a family, even in the face of biological and social barriers. The decision to have children is a personal one and we support families of all shapes and sizes. Having the right information empowers people to make the right decision at the right time, and demystifying infertility allows thoughtfulness and empathy to grow within communities and workplaces to better support their friends, families, and employees. The "Real Voices, New Insights: Eureka Moments for Fertility in Asia" white paper was commissioned by Ferring in collaboration with Weber Shandwick to provide insights into the journey towards parenthood based on EUREKA – a large scale survey conducted across the Asia Pacific region, supported by various peer-reviewed publications and experts’ opinion. It provides a concise, reliable, and informative resource that could be used to guide more couples in realizing their dreams of building a family. The full white paper is now available at https://re.ferring.com/eureka.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References
1 "Ipsos Pte Ltd, Singapore (2022). Study on key Asian insights in family building dreams (EUREKA), unpublished"
2 "Ipsos Limited, Taiwan (2022). Infertility patient and partner survey: 1000 Dreams in Taiwan (EUREKA), unpublished"
3 World Health Organization. Infertility. Available at: https://www.who.int/news-room/fact-sheets/detail/infertility
4 ASRM. Age and Fertility – A Guide for Patients: Available at: https://www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/factsheets-and-info-booklets/age-and-fertility/. Accessed Mar 2023.
5 Sax MR & Lawson AK. Women 2022; 2:68–75.

Source : Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondents expressed a low to moderate level of knowledge about infertility and conception.  Unexpected emotional burden and fear emerged as primary factors causing delays in seeking medical treatment. The journey was marked by a rollercoaster of emotional highs and lows.1,2

TAIPEI, Nov. 7, 2023 /PRNewswire/ — Today, Ferring Pharmaceuticals released a white paper report titled "Real Voices, New Insights: Eureka Moments for Fertility in Asia" integrating findings from a multi-country survey ("EUREKA") across seven countries in Asia involving over 1,465 respondents who were considering, receiving, or have completed fertility treatments.1,2 Supported by publications and experts’ opinion, the insights reported can help guide couples, the public and governments to better understand the infertility journey in light of the declining births crisis emerging in many Asian countries and regions, including here in Taiwan.

"Many Asian countries are facing an unprecedented decline in birth rates. As a leader in reproductive medicine, Ferring is committed to building families worldwide and supporting the journey to parenthood. The EUREKA survey is one of the first in our region involving seven countries highlighting the increasing importance to understand the emotional journey of many couples to increase education and community awareness" said Alex Chang, Senior Vice President of Asia Pacific, Middle East, and Africa, Ferring Pharmaceuticals.

The journey of conception is long for many couples in Asia
The white paper reported that the fertility journey of survey respondents – from deciding to have a baby, diagnosis, treatment to eventual conception – took an average of 6.8 years, out of which, an average of 3.6 years trying to conceive naturally,1,2 which is more than three times the duration recommended by the World Health Organization in defining infertility warranting medical consultation.3

Notably, those living in countries and regions such as Japan, Korea, Taiwan and Singapore – where fertility treatments are covered by national health schemes either through reimbursements or subsidies, reported an average of 1.6 years after diagnosis to start treatment.1,2 Age and duration impact conception success.4 It is thus important to raise awareness on seeking professional advice sooner as waiting may lead to a lower chance of successful conception owing to older age.

Associate Professor Sadhana Nadarajah, Head and Senior Consultant, Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, said that "[a] woman’s age is an important determinant of fertility. With increasing age, both egg quality and quantity decline, especially after 35. By the age of 40, only 20–30 percent of those who wish to have a baby will be able to do so."

Echoing the role that age plays in one’s fertility journey, Dr Chen Mei-Jou, President of Taiwanese Society for Reproductive Medicine, mentioned that "there is an obvious and significant difference in terms of the success rate of IVF treatment at the ages of 35, 38 and above 40. In Taiwan, the biggest problem encountered by fertility physicians is that patients often seek help very late into their fertility journey, and some may have even waited for years after trying to conceive naturally."

Knowledge gaps inevitably delay the fertility journey
It was identified that there was a general lack of understanding and lots of misconceptions of infertility. Many were unfamiliar with key fertility concepts, inadvertently delaying taking the first step towards family planning.  

At least seven out of 10 respondents from Indonesia, Japan, Korea, Singapore and Vietnam self-reported low-to-moderate knowledge of infertility and conception before they were diagnosed with fertility issues. They had limited knowledge about key fertility concepts and wished they had known earlier:1

How infertility affects both genders How age impacts the quantity and quality of eggs, or ovarian reserve, which influences the overall chances of natural conception How the success of fertility treatments can be age-dependent despite medical advances

Dr Chen Mei-Jou, President of Taiwanese Society for Reproductive Medicine, mentioned that "it is important to educate the public that fertility issues, including secondary infertility, affect both women and men in equal measures."

Respondents from the survey also indicated that they depended heavily on online platforms and channels as a key source of fertility-related information which was identified in the report to be at high risk of misinformation and bias.1,2  

Emotional support is critical

The report also highlighted findings on the emotional rollercoaster the respondents underwent. Regardless of treatment outcomes, the diagnosis and treatment of infertility was a highly emotional experience. Psychological factors are among the most frequently cited reasons for patients dropping out of fertility treatments, often in the earliest stages of treatment.5 In Asia, the EUREKA survey found that couples often struggled with high levels of emotional strain:1,2 

Unexpected emotional burden was a major pain point for respondents in their treatment journey and fear was often cited as a primary reason against starting treatment for those who did not proceed. In Taiwan, 13 percent of respondents cited unexpected emotional burden and fear of treatment response as top barriers during their treatment journey. A high proportion (63 percent) also indicated unexpected treatment costs as a major pain point. Unexpected emotional burden was a major pain point and fear was often cited as a primary reason against starting treatment. At all timepoints, there was a fluctuation between positive and negative emotions. Even for respondents who achieved successful conception, considerable negative emotions continued to persist. The prolonged mix of emotions can be of significant burden to the couple and their motivation to continue.

For example, in Singapore, men and women were equally anxious at diagnosis. Katy, a 38-year-old from Singapore, shared that "the period of trying to achieve pregnancy is something that is hard to forget. All the injections, reviews, waiting, hope, and anticipation. In many cases, couples would have to try again and again to succeed, and it gets even harder with each failure."  

While countries and regions including Singapore, Japan, Korea, and Taiwan have started recognizing the growing need to increase access to infertility treatments through various national financial coverage schemes, emotional support remains a missing piece for many. At present, mental health remains underprioritized in the treatment of infertility and the provision of emotional support from various sources is critical.

About the White Paper – Real Voices, New Insights: Eureka Moments for Fertility in Asia
Everyone has a right to build a family, even in the face of biological and social barriers. The decision to have children is a personal one and we support families of all shapes and sizes. Having the right information empowers people to make the right decision at the right time, and demystifying infertility allows thoughtfulness and empathy to grow within communities and workplaces to better support their friends, families, and employees. The "Real Voices, New Insights: Eureka Moments for Fertility in Asia" white paper was commissioned by Ferring in collaboration with Weber Shandwick to provide insights into the journey towards parenthood based on EUREKA – a large scale survey conducted across the Asia Pacific region, supported by various peer-reviewed publications and experts’ opinion. It provides a concise, reliable, and informative resource that could be used to guide more couples in realizing their dreams of building a family. The full white paper is now available at https://re.ferring.com/eureka.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

References
1 "Ipsos Pte Ltd, Singapore (2022). Study on key Asian insights in family building dreams (EUREKA), unpublished"
2 "Ipsos Limited, Taiwan (2022). Infertility patient and partner survey: 1000 Dreams in Taiwan (EUREKA), unpublished"
3 World Health Organization. Infertility. Available at: https://www.who.int/news-room/fact-sheets/detail/infertility
4 ASRM. Age and Fertility – A Guide for Patients: Available at: https://www.reproductivefacts.org/news-and-publications/patient-fact-sheets-and-booklets/documents/factsheets-and-info-booklets/age-and-fertility/. Accessed Mar 2023.
5 Sax MR & Lawson AK. Women 2022; 2:68–75.

Source : Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Who’s Who Legal (WWL) publication, WWL Southeast Asia 2023, recognizes global consulting firm J.S. Held experts in Singapore as industry leaders in construction, arbitration, and investigations.

SINGAPORE, Nov. 7, 2023 /PRNewswire/ — Global consulting firm J.S. Held celebrates experts in Singapore who have been recognized as industry leaders in construction, arbitration, and investigations in Who’s Who Legal (WWL) publication, WWL Southeast Asia 2023.

Construction & Arbitration Expert Witnesses 2023

John Lancaster, Construction Advisory, is a Senior Managing Director with J.S. Held. As a Chartered Mechanical Engineer with 39 years of international experience in oil & gas, mining & metallurgy, and power & energy sectors, John has been appointed 50 times including multi-billion-dollar disputes, making him a distinguished Global Leader in construction and arbitration, recognized by WWL Construction Expert Witnesses 2023 and Arbitration Expert Witnesses 2023.

WWL says:

"John Lancaster is a highly sought-after expert with a strong reputation in the market and a wealth of experience in delay issues."

Arbitration Expert Witnesses 2023

Iain Potter, Economic Damages & Valuations Expert, is an Executive Vice President with J.S. Held. As a qualified Chartered Accountant, Iain Potter has been recognized as a National Leader of Arbitration Expert Witnesses 2023 by WWL. Iain specializes in complex loss of profit and valuation engagements and Iain’s extensive experience spans multiple continents and industries.

WWL says:

"Iain Potter’s ‘enthusiasm and willingness to go the extra mile to understand and complete the assignment in a timely manner’ earns him widespread plaudits among market observers."

Asset Recovery Experts 2023; Investigation 2023

Bruno Vickers, Global Investigations Expert, is a Managing Director with J.S. Held. Bruno Vickers is a seasoned expert with vast experience in global investigations ranging from due diligence on transactions to complex fraud and dispute resolution. With a decade of experience, Bruno excels in assisting clients in locating and recovering assets in cross-border disputes and has been recognized as the Global Leader of Asset Recovery Experts 2023 and Investigations 2023 by WWL.

WWL says:

"Bruno Vickers is praised as ‘an excellent investigator with a strong commercial understanding of his clients’ issues’ and experience in major cross-border investigations."

Construction & Arbitration Expert Witnesses 2023

Matthew Wills, Construction Advisory, is a Senior Managing Director with J.S. Held. With over 29 years of extensive experience in the oil & gas, engineering, procurement, and construction industries across 25+ countries, Matthew Wills has been recognized as the Global Leader of WWL Construction Expert Witnesses 2023 and Arbitration Expert Witnesses 2023. As a renowned expert witness on both quantum and technical matters, Matthew has been appointed as an expert on 48 occasions and testified on numerous occasions worldwide.

WWL says:

"Matthew Wills is a top-notch quantum expert with a high-profile practice who ‘always performs well in the stand.’"

J.S. Held in Asia Pacific combines global experience with local market insights to provide technical, scientific, and financial expertise across all assets and value at risk.

About J.S. Held

J.S. Held is a global consulting firm providing technical, scientific, financial, and strategic expertise across all assets and value at risk. Our professionals serve as trusted advisors to organizations facing high-stakes events demanding urgent attention, staunch integrity, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice. Securities offered through PM Securities, LLC, d/b/a Phoenix IB, a part of J.S. Held, member FINRA/ SIPC or Ocean Tomo Investment Group, LLC, a part of J.S. Held, member FINRA/ SIPC. All rights reserved.

Contact

Kristi L. Stathis

Global Public Relations

J.S. Held, LLC

[email protected]

+1 786 833 4864

Source : Who's Who Legal Southeast Asia 2023 Recognizes Global Consulting Firm J.S. Held and Experts

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

— Clover’s seasonal influenza vaccine BLA submission has been completed in Brazil, boosting Clover’s global presence — 

SHANGHAI, Nov. 7, 2023 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the company completes the Biologic License Application (BLA) submission for its seasonal influenza vaccine (AdimFlu-S) to Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, or ANVISA). Upon approval, Clover will work with its local partner to commercialize the product in Brazil. 

"The BLA submission of AdimFlu-S in Brazil is another step towards our goal of becoming a global leader in the respiratory vaccine space and builds upon Clover’s prior experience enrolling over 10,000 people in clinical trials across Brazil and South America," said Joshua Liang, Chief Executive Officer and Executive Director of Clover, "By leveraging our unique globalization capabilities, we will continue expanding to other countries and regions to diversify our sales and maximize our impact on public health." 

If approved in Brazil, Clover’s seasonal influenza vaccine would have access to the Southern Hemisphere market, enabling annual sales in the first half of the year to supplement sales in the second half of the year in Northern Hemisphere markets such as China, while also better utilizing Adimmune’s production capacity year-round. Brazil is an important vaccine market strategically, as the country has the world’s second largest seasonal influenza vaccine market, with total local market size expected to surpass US$1 billion over the next 5 years, according to Globaldata.  

About Clover 

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.  

Clover Forward-looking Statements  

This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.  

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.  

Clover Biopharmaceuticals:  

Corporate Communication: Lola Cao  

[email protected] 

Investor Relations: Elaine Qiu  

[email protected] 

Source : Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Commerce Secretary says the new office will help the Economic Development Partnership of North Carolina attract investors and trade partners across Southeast Asia

TAIPEI, Nov. 7, 2023 /PRNewswire/ — In partnership with the Economic Development Partnership of North Carolina (EPDNC), N.C. Department of Commerce Secretary Machelle Baker Sanders announced today that North Carolina has opened its first Taiwan investments office. The State of North Carolina Taiwan Office, located in Taipei, opened October 5 and aims to secure investment partnerships from Southeast Asian companies and organizations, including those in mainland China and Taiwan.

"Opening an office in Taiwan solidifies North Carolina’s commitment to fostering global partnerships, strengthening international ties and promoting economic growth," said North Carolina Secretary of Commerce Machelle Baker Sanders. "The state has seen more than $5.1 billion invested from Southeast Asian companies since 2013, and we will continue to build bridges connecting North Carolina to the world, enhancing opportunities for trade, innovation and partnerships."

Taiwanese companies who have made investments in North Carolina, including Anderson Group, HTC Global Services, Everest Textiles, Delta Electronics and more, have pledged more than $52 million in investments and 846 jobs in North Carolina since 2013. The Tar Heel state has exported $372.6 million in trade and goods to Taiwan in 2022 and imported $1.68 billion. According to the U.S. Department of State, Taiwan is one of the world’s top 20 economies in terms of gross domestic product (GDP) and serves as the United States’ ninth-largest trading partner.

"Taiwanese companies are increasing foreign direct investment in the U.S., notably led by the microelectronic and clean energy sectors," said Christopher Chung, CEO of the Economic Development Partnership of North Carolina (EDPNC). "North Carolina recognizes the resiliency of Taiwan business across many sectors and values a stronger partnership built on our commitment to innovation, collaboration, and continued growth. As a Taiwanese American whose parents immigrated from Taiwan, I am thrilled North Carolina is furthering its relationship with Taiwan. The EDPNC and I look forward to establishing our Taiwan office to connect with Taiwanese and other regional businesses and stakeholders to promote North Carolina as an ideal business location."

The Taiwan office will be North Carolina’s ninth international location, following offices in Canada, Japan, Mexico, Singapore, Germany, Poland, Belgium and Dubai.

CNBC named North Carolina its Top State for Business in 2022 and 2023. Last year saw a record-breaking $19.3 billion invested in the state and nearly 29,000 new jobs announced, including 10,275 from 30 foreign direct investment projects worth a combined $5.21 billion.

For more information, visit https://edpnc.com/.

About the Economic Development Partnership of North Carolina

The Economic Development Partnership of North Carolina (EDPNC) is a private nonprofit corporation that serves as North Carolina’s statewide economic development organization. Governed by an 18-member board of business and industry leaders from across the state, the EDPNC focuses on business and job recruitment, existing industry support, international trade, and tourism and film marketing. The EDPNC, which operates under contract with the North Carolina Department of Commerce, works closely with public- and private-sector partners at the state, regional and local levels. For more information, visit edpnc.com.

Source : North Carolina Opens First Office for Economic Development in Taiwan

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Currently plays for Daejeon JUNG KWAN JANG Red Sparks Renowned for powerful serve and impressive jumps

SEOUL, South Korea, Nov. 7, 2023 /PRNewswire/ — Just like many other sports, each country has its own popular sports due to cultural, historical and environmental factors. Indonesia is famous for badminton, while Thailand excels in women’s volleyball. Singapore stands out in badminton, tennis and table tennis, while Vietnam and Malaysia are recognized for their fever in soccer.

South Korea, a country with numerous professional sports leagues, receives significant popularity. Particularly, in the women’s professional volleyball league. This month, Megawati Pertiwi of the Daejeon JUNG KWAN JANG Red Sparks has become a star player, drawing high expectations with her excellent plays. Megawati Pertiwi, an Indonesian opposite spiker, said that she endured all challenging training sessions by taking red ginseng daily. This routine has led to consistent high scores in every game since the league’s opening match.

In South Korea, where many professional sports leagues thrive, several companies contribute to athlete development by sponsoring sports teams. The world’s No.1 ginseng brand, JUNG KWAN JANG, for ten consecutive years, supports basketball, volleyball, table tennis, badminton, and Go. The badminton team, established in 1969, holds the longest history in Korea. The JUNG KWAN JANG Red Boosters, a professional basketball team featuring former Philippine national basketball player Rhenz Abando, won both the regular season and championship titles in the 2022-2023 season. The team shared that they enhanced their physical strength and endurance with JUNG KWAN JANG red ginseng supplements. The JUNG KWAN JANG CheonNok, a professional Go team that secured the regular season championship in 2022-2023, also relied on JUNG KWAN JANG red ginseng to maintain their focus during long games.

With a 124-year history and a rich tradition, JUNG KWAN JANG red ginseng has received official recognition from the Korean Ministry of Food and Drug Safety for improving immunity, fatigue, memory, blood flow by mitigating aggregation of platelet, and antioxidation.  

In practice, Koreans frequently carry red ginseng products while exercising, traveling or going on business trips to boost their stamina and immunity. In 2012, JUNG KWAN JANG launched ‘Korean Red Ginseng Extract Everytime,’ a convenient small pouch designed for easy consumption, gaining huge popularity among the public.

Player Megawati Pertiwi of the Daejeon JUNG KWAN JANG Red Sparks and Korean Red Ginseng Extract Everytime

Source : Megawati Pertiwi, a volleyball player from Indonesia, attributes her vibrant and healthy energy to rigorous training and the intake of red ginseng

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network